Skip to main navigation Skip to search Skip to main content

52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis’. Canadian Rheumatology Association (CRA), Ottowa, Feb 2017.

Research output: Contribution to conference › Poster

Original languageAmerican English
StatePublished - Feb 2017
EventCanadian Rheumatology Association (CRA) -
Duration: Feb 1 2017 → …

Conference

ConferenceCanadian Rheumatology Association (CRA)
Period02/1/17 → …

Disciplines

  • Rheumatology

Cite this